OUR RESEARCH

We study gynecologic diseases to understand their fundamental biology and translate discoveries into better prevention, detection, and treatment.

Decode·Design·Deliver
OVARIAN CANCER
The most lethal gynecologic malignancy.

High-grade serous disease responds to first-line chemotherapy, only to return with resistance. Immunotherapies that transformed other cancers have barely moved the needle here. We study why treatments fail and develop new therapeutic strategies.

<50%
FIVE-YEAR SURVIVAL
More info soon
ENDOMETRIOSIS
Chronic, under-studied, high-impact.

Affects 1 in 10 women, causing pain, infertility, and 7–10 years of diagnostic delay. Advanced lesions carry up to a 10-fold elevated risk of ovarian cancer. We're applying the tools that transformed cancer research to close this gap.

1 in 10
WOMEN AFFECTED
More info soon
OUR APPROACH

We integrate experimental and computational methods to understand disease at unprecedented resolution.

01
Single-cell & spatial genomics

We profile individual cells to reveal hidden diversity and cell states, and we map how those cells are organized in tissue. scRNA-seq, snPATHO-seq, and Xenium.

02
Patient-derived disease models

We build organoid and primary cell models from patient samples. These systems reflect human biology and let us test findings and therapeutics.

03
Computational biology

Cell-state inference, spatial neighborhood analysis, trajectory modeling, and integration across modalities.

04
Ottawa GynePath Biobank

Our research is powered by patient-contributed samples and clinical data, grounding every project in human biology from the start.

More info soon
WHAT WE'RE ASKING
OVARIAN CANCER
Why do high-grade serous ovarian cancers become resistant to chemotherapy after a strong initial response?
Treatment resistance
How does the biology of rare ovarian cancer subtypes differ from high-grade serous disease?
Rare subtypes
Why have immunotherapies failed in ovarian cancer?
Novel immunotherapies
ENDOMETRIOSIS
Can we detect endometriosis earlier?
Early detection
Can developments in cancer therapeutics improve outcomes for women with endometriosis?
Novel immunotherapies
How does endometriosis develop into ovarian cancer?
Progression